Drug development
Genomic information about an individual can be of considerable
importance to the process of developing drugs while they await FDA
approval for public use. When determining whether a patient should be
included or excluded in the final stages of a clinical trial, a detailed
understanding of a patient’s genetic make-up is invaluable [13]
Identifying patients who will benefit most from a clinical trial will
increase patient safety and endanger adverse effects from the testing
product, and smaller and faster trials will entail lower costs [19].
Furthermore, drugs that are ineffective for a larger portion of the
population can gain approval by the FDA depending on the personal
genomes used to evaluate the effectiveness and necessity of the specific
medicine, even though the majority may not require it.